# Madrigal Pharmaceuticals

Type: Company (MDGL)

Source: GetYourBrief — https://getyourbrief.com/entity/madrigal-pharmaceuticals
Canonical HTML page: https://getyourbrief.com/entity/madrigal-pharmaceuticals

## Timeline

- **2026-01-01**: Payer Agreement Shift — New payer contracts take effect, shifting GTN expectations to the high 30% range for the fiscal year.
- **2025-12-31**: Q4 Milestone — Patient count surpasses 36,000 and quarterly revenue exceeds $320 million.
- **2025-12-31**: Patent Extension — Secured Rezdiffra patent protection through 2045.
- **2025-11-20**: DGAT-2 and siRNA Expansion — Acquired late-stage DGAT-2 inhibitor and six preclinical siRNA assets.
- **2025-09-30**: GLP-1 Strategic Acquisition — Madrigal makes a $120 million upfront payment for an oral GLP-1 asset to expand its metabolic pipeline.
- **2025-09-15**: GLP-1 Acquisition — Madrigal paid $120 million upfront to acquire an oral GLP-1 program.
- **2025-03-01**: Rezdiffra Commercial Launch — First full year of Rezdiffra availability in the U.S. market for MASH.
- **2025-01-01**: Rezdiffra Full-Year Launch — Madrigal begins its first full year of commercial sales for the first-ever approved MASH treatment.

## Recent coverage (3 stories, network-wide)

### Madrigal’s Rezdiffra Surpasses $950M in 2025 as Pipeline Expands into GLP-1s
2026-02-24 00:14:25 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 5

Madrigal Pharmaceuticals reported a transformative 2025, with Rezdiffra net sales reaching $958.4 million during its first full year on the market. The company is aggressively pivoting toward a multi-asset metabolic powerhouse, integrating oral GLP-1 and DGAT-2 programs alongside its core MASH franchise.
Full story: https://getbiobrief.com/story/madrigal-pharma-q4-2025-earnings-rezdiffra-growth

### Q4 Earnings: Carvana and Freshpet Lead Digital-First Retail Surge
2026-02-24 00:10:34 · Sector: retail · Sentiment: Positive · Impact: 7/10 · Sources: 5

The Q4 2025 earnings cycle reveals a retail landscape defined by digital efficiency and premiumization, with Carvana and Freshpet posting double-digit volume growth. Companies are increasingly leveraging loyalty ecosystems and strategic partnerships to drive margins in a stabilizing consumer market.
Full story: https://getretailbrief.com/story/q4-2025-ecommerce-retail-earnings-analysis

### Madrigal Pharmaceuticals Triples Q4 Revenue as Rezdiffra Adoption Accelerates
2026-02-24 00:09:59 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 5

Madrigal Pharmaceuticals reported a transformative Q4 2025, with Rezdiffra net sales reaching $321.1 million and a patient base exceeding 36,000. The company is aggressively expanding its metabolic pipeline, integrating GLP-1 and siRNA technologies to solidify its leadership in the MASH market.
Full story: https://gethealthbrief.com/story/madrigal-q4-2025-earnings-rezdiffra-mash-market

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.